Since there is an active discussion with the recent trial news I thought to ask if anyone is familiar Neurotrope (NTRP, http://www.neurotropebioscience.com/ ) and/or their drug Bryostatin 1.
I have no investment interest at this time but would like to see something work in AD. They have data reporting in April from a 148 patient study in moderate to severe patients.
The most disappointing thing in some of the recent failures is the bar seemed quite low in the studies, i.e. even if successful would these treatments have resulted in a significant slowdown of the disease? The size/duration of these studies suggests to me the benefit would have been small.
News 
Market Data 
Discover 
